 Capricor Therapeutics Inc NASDAQ: CAPR has announced final data from Phase 2 HOPE-2 trial of CAP-1002 for advanced stages of Duchenne muscular dystrophy DMD. The trial met its primary efficacy endpoint of mid-level performance of upper limb mid-PUL v1.2 and various skeletal and cardiac function endpoints. 